Immune Checkpoint-Engineered Virus-Like Particles Induce Antigen-Specific Immune Tolerance and Protect against Food Allergy

Scientist developed a novel class of tolerogenic vaccines based on recombinant virus-like particles, engineered to display the immune checkpoint molecule CTLA-4 on their surface and incorporate specific antigens.